Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Edwards Lifesciences | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The aim of the present work is to describe the hemodynamic effects shown in patients with ARDS secondary to SARS-CoV-2 infection
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Description Group |
|
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Total amount of hypotension | Hypotension will be defined as a hemodynamic event that occurs when the MAP falls below 65 mmHg for a minimum duration of 1 minute (3 consecutive recordings of 1 minute or more between two consecutive falls of the MAP). | 5 days |
| Measure | Description | Time Frame |
|---|---|---|
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Stroke volume) | We will obtain hemodynamic data for the first 5 days after the patient enters the study | 5 days |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Stroke volume variation) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with ARDS secondary to SARS-CoV-2 infection
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Juan Victor Lorente, MD | Contact | 695881448 | juanvictor.lorente@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 1. A.H. Juan Ramón Jiménez. | Huelva | Andalusia | 21005 | Spain |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
We will obtain hemodynamic data for the first 5 days after the patient enters the study |
| 5 days |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Cardiac index) | We will obtain hemodynamic data for the first 5 days after the patient enters the study | 5 days |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor ( HPI) | We will obtain hemodynamic data for the first 5 days after the patient enters the study | 5 days |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (Eadyn) | We will obtain hemodynamic data for the first 5 days after the patient enters the study | 5 days |
| Minimally invasive hemodynamic monitoring and related variables obteined from HemoSphere platform with Acumen IQ sensor (dp/dt max,) | We will obtain hemodynamic data for the first 5 days after the patient enters the study | 5 days |
| Presence of treatment with noradrenaline; presence of treatment with dobutamine, presence of treatment with other vasoactive/ionotropic/hypotensive drugs | start time, time of dose change, current dose | 5 days |
| Furosemide treatment | dose/24 hours | Daily during 5 days |
| Daily diuresis, daily water balance, accumulated water balance since ICU admission, daily parenteral nutrition volume, and daily enteral nutrition volume. | ml/24 h | Daily during 5 days |
| Atrial fibrillation | Presence, start time and end time | 5 days |
| Acute kidney injury | Presence and degree with KDIGO definition | Daily during 5 days |
| Continuous renal replacement therapies | Start and end date/time, dialyzing flow, replacement flow, daily balance. | 5 days |
| Need for Hemadsorption | Start and end date/time, blood flow. | 5 days |
| Specific treatment for SARS-CoV2 (presence of tocilizumab, antimalarial drugs, antivirals) | Start and end date/time | 5 days |
| Corticoid treatment. | Start and end date/time | 5 days |
| 5. Hospital Virgen de la Victoria | Málaga | Andalusia | Spain |
|
| 4. Hospital Universitario de Álava. | Alava | Basque Country | Spain |
|
| 3. Hospital Universitario. Jerez de la Frontera. | Jerez de la Frontera | Cádiz | Spain |
|
| 2. Hospital Universitario Infanta Leonor | Madrid | Spain |
|
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |